https://doi.org/10.4081/ltj.2024.390
Frequency-doubled neodymium yttrium aluminum garnet (Nd:YAG) laser trabeculoplasty as adjuvant therapy for open-angle glaucomas
Submitted: 2 February 2024
Accepted: 31 March 2024
Published: 22 April 2024
Accepted: 31 March 2024
Abstract Views: 83
PDF: 33
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The thermal frequency-doubled Nd:YAG (neodymium: yttrium-aluminum-garnet) laser was used sparingly for trabeculoplasty. Our goal was to assess the efficacy and safety of frequency-doubled Nd:YAG laser trabeculoplasty as an adjunct therapy to anti-glaucoma medications in open-angle glaucoma. Laser trabeculoplasty was performed on 41 eyes of 22 adults with open-angle glaucomas using a thermal frequency-doubled Nd:YAG laser (Green laser photocoagulator GYC-500® 532 nm, Nidek, Japan). To assess the laser’s effectiveness, patients were monitored for intraocular pressure (IOP) reduction, control, and complications at 1 hour, 1 week, and then monthly for a year. Primary open-angle glaucoma was the most common diagnosis in 31 (75.6%) eyes. The pre-laser baseline IOP was 18.87±3.66 mmHg. The mean IOP was 14.9±2.54 mmHg at Week 1 (p = 0.000), 14.65±2.50 mmHg at Month 1, 14.53±2.60 mmHg at Month 3, 15.85±2.30 mmHg at Month 6, and 15.14±2.17 mmHg at Month 12 (p=0.000). A significant percentage reduction in IOP was achieved at 1, 3, 6, and 12 months: 21.78%, 22.48%, 16.73%, and 18.53%, respectively. Patients used an average of 2.73±1.00 topical drugs before laser treatment. There was a significant reduction in medicines after laser treatment on all occasions, at 1, 3, 6, and 12 months (p = 0.000). Complications included some degree of peripheral anterior synechiae (PAS) in 20 (51.3%) eyes; an IOP spike in one patient only, bilaterally (5.1%) at 1 hour after therapy; and mild anterior uveitis in four (9.75%) cases. To summarize, frequency-doubled Nd:YAG laser trabeculoplasty is a safe and effective adjuvant therapy for open-angle glaucoma that reduces intraocular pressure and medication use.
Glaucoma Research Foundation. January is glaucoma awareness month. 2019; San Francisco, CA (USA): Glaucoma Research Foundation; [cited 11 August 2019] Available from: https://www.glaucoma.org/news/glaucoma-awareness-month.php
World Health Organization. Blindness and vision impairment prevention: Priority eye diseases. Glaucoma (2019) Geneva: World Health Organization; [cited 11 August 2019] Available from: https://www.who.int/blindness/causes/priority/en/index6.html
Lusthaus J, Goldberg I. Current management of glaucoma. Med J Aust 2019;210:180-7.
DOI: https://doi.org/10.5694/mja2.50020
Ekici F, Waisbourd M, Katz LJ. Current and future of laser therapy in the management of glaucoma. Open Ophthalmol J 2016;10:56-67.
DOI: https://doi.org/10.2174/1874364101610010056
Garg A, Gazzard G. Selective laser trabeculoplasty: Past, present, and future. Eye 2018;32:863-76.
DOI: https://doi.org/10.1038/eye.2017.273
Yanoff M, Duker JS. Ophthalmology. Third Edition. Mosby: St. Louis, 2009 p. 1227-88.
Tsang S, Cheng J, Lee JW. Developments in laser trabeculoplasty. Br J Ophthalmol 2016;100:94-7.
DOI: https://doi.org/10.1136/bjophthalmol-2015-307515
Abramowitz B, Kouchouk A, Ahabshan R, et al. Selective laser trabeculoplasty vs Micropulse laser trabeculoplasty in open angle glaucoma. Clin Ophthalmol 2018;12:1599-604.
DOI: https://doi.org/10.2147/OPTH.S167102
Espinoza G, Castellanos L, Rodriguez-Una I, et al. Clinical outcomes of patterned laser trabeculoplasty as adjuvant therapy in open angle glaucomas and ocular hypertension. Int J Ophthalmol 2018;11:635-40.
Zhang AY, Kumar D, Tripathy K. Laser Principles in Ophthalmology. 2023 Aug 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–.
Ritch R, Tham CCY. Chapter 44 - Laser peripheral iridotomy and iridoplasty. Editors: Spaeth GL, Danesh-Meyer HV, Ivan Goldberg I, Kampik A. Ophthalmic Surgery: Principles and Practice. Fourth Edition, Saunders, 2012;308-17.
DOI: https://doi.org/10.1016/B978-1-4377-2250-5.00044-8
Brodie SE, Ang M, Irsch K, her SM, et al. Clinical Optics and Vision Rehabilitation. Section 3. Basic and Clinical Science Course. American Academy of Ophthalmology. San Francisco. 2022-2023; p 132-7.
Kwasniewska S, Fankhauser F, Larsen SE, et al. The efficacy of cw Nd:YAG laser trabeculoplasty. Ophthalmic Surg 1993;24:304-8.
DOI: https://doi.org/10.3928/1542-8877-19930501-06
Agarwal HC, Poovali S, Sihota R, et al. Comparative evaluation of diode laser trabeculoplasty vs frequency doubled Nd: YAG laser trabeculoplasty in primary open angle glaucoma. Eye (Lond) 2006;20:1352-6.
DOI: https://doi.org/10.1038/sj.eye.6702108
Bowing B. Kanski’s Clinical Ophthalmology. A systematic approach. Eighth Edition. Elsevier: China; 2016; 334-57.
Sihota R, Angmo D, Deepa R, et al. Simplifying “target” intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol 2018;66:495-505.
DOI: https://doi.org/10.4103/ijo.IJO_1130_17
Holló G. Argon and low energy pulsed Nd:YAG laser trabeculoplasty. A prospective, comparative clinical and morphological study. Acta Ophthalmol Scand 1996;74:126-31.
DOI: https://doi.org/10.1111/j.1600-0420.1996.tb00055.x
Robin AL, Pollack IP. Q-switched neodymium-YAG laser angle surgery in open-angle glaucoma. Arch Ophthalmol 1985;103:793-5.
DOI: https://doi.org/10.1001/archopht.1985.01050060053023
Mahar PS, Jamali KK. Argon laser trabeculoplasty as primary therapy in open angle glaucoma. JCPSP 2008;18:102-4.
Fasih U, Shahid E, Sheikh A. Efficacy and safety of Argon laser trabeculoplasty in lowering intraocular pressure as adjunctive treatment to primary open angle glaucoma. Pak J Ophthalmol 2019;35:9-14.
DOI: https://doi.org/10.36351/pjo.v35i1.856
Gračner T. Comparative study of the efficacy of selective laser trabeculoplasty as initial or adjunctive treatment for primary open-angle glaucoma. Eur J Ophthalmol 2018;1120672118801129.
DOI: https://doi.org/10.1177/1120672118801129
Kurysheva NI, Lepeshkina LV, Shatalova EO. Predictors of outcome in selective laser trabeculoplasty: a long-term observation study in primary angle-closure glaucoma after laser peripheral iridotomy compared with primary open-angle glaucoma. J Glaucoma 2018;27:880-6.
DOI: https://doi.org/10.1097/IJG.0000000000001048
Belitsky Y, Škiljić D, Zetterberg M, et al. Evaluation of selective laser trabeculoplasty as an intraocular pressure lowering option. Acta Ophthalmol 2019;97:707-13.
DOI: https://doi.org/10.1111/aos.14067
Dorin G. New Laser Technologies. In: Samples JR, Ahmed IIK (eds) Surgical Innovations in Glaucoma. Springer, New York, NY. 2014. http://doi-org-443.webvpn.fjmu.edu.cn/10.1007/978-1-4614-8348-9_7
DOI: https://doi.org/10.1007/978-1-4614-8348-9_7
Abdelrahman AM. ElSaied HM, Allam RS, et al. Wipe-out after subscleral trabeculectomy in advanced glaucoma patients. Delta J Ophthalmol 2017;18:94-8.
DOI: https://doi.org/10.4103/DJO.DJO_44_16
Kumar H, Mansoori T, Warjri GB, et al. Lasers in glaucoma. Indian J Ophthalmol 2018;66:1539-53.
DOI: https://doi.org/10.4103/ijo.IJO_555_18
Van de viere S, Zeyen T, Stalmans I. Argon versus selective laser trabeculoplasty. Bull Soc Belge Ophtalmol 2006;299:5-10.
Wang W, He M, Zhou M, et al. Selective laser trabeculoplasty versus Argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis. PLoS One 2013;8:e84270.
DOI: https://doi.org/10.1371/journal.pone.0084270
Khouri AS, Lari HB, Berezina TL, et al. Long term efficacy of repeat selective laser trabeculoplasty. J Ophthalmic Vis Res 2014;9:444-8.
DOI: https://doi.org/10.4103/2008-322X.150814
Zhou Y, Aref AA. A review of Selective laser trabeculoplasty: Recent findings and current perspectives. Ophthalmol Ther 2014;6:19-32.
DOI: https://doi.org/10.1007/s40123-017-0082-x
Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. LiGHT Trial Study Group. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 2019;393:1505-16.
DOI: https://doi.org/10.1016/S0140-6736(18)32213-X
Hutnik C, Crichton A, Ford B, et al. Selective laser trabeculoplasty versus argon laser trabeculoplasty in glaucoma patients treated previously with 360° selective laser trabeculoplasty: a randomized, single-blind, equivalence clinical trial. Ophthalmology 2019;126:223-32.
DOI: https://doi.org/10.1016/j.ophtha.2018.09.037
Song JSA, Vianna J, Shuba L, et al. Evaluating selective laser trabeculoplasty versus argon laser trabeculoplasty in pseudoexfoliation glaucoma patients. Can J Ophthalmol 2018;53:70-5.
DOI: https://doi.org/10.1016/j.jcjo.2017.07.004
Marshall LL, Hayslett RL, Stevens GA. Therapy for Open-Angle Glaucoma. Consult Pharm 2018;33:432-45.
DOI: https://doi.org/10.4140/TCP.n.2018.432
De Keyser M, De Belder M, De Belder S, De Groot V. Where does selective laser trabeculoplasty stand now? A review. Eye Vis (Lond) 2016;3:10.
DOI: https://doi.org/10.1186/s40662-016-0041-y
Katsanos A, Konstas AG, Mikropoulos DG, et al. A review of the clinical usefulness of selective laser trabeculoplasty in exfoliative glaucoma. Adv Ther 2018;35:619-30.
DOI: https://doi.org/10.1007/s12325-018-0695-z
De Keyser M, De Belder M, De Belder J, et al. Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients. Acta Ophthalmol 2017;96:13509.
DOI: https://doi.org/10.1111/aos.13509
Bergeå B. Some factors affecting the intraocular pressure reduction after Argon laser trabeculoplasty in open-angle glaucoma. Acta Ophthalmol (Copenh) 1984;62:696-704.
DOI: https://doi.org/10.1111/j.1755-3768.1984.tb05796.x
Richardson LE. Argon laser trabeculoplasty: a review. J Am Optom Assoc 1992;63:252-6.
Abdelrahman AM. Non-invasive glaucoma procedures: Current options and future innovations. Middle East Afr J Ophthalmol 2015;22:2-9.
DOI: https://doi.org/10.4103/0974-9233.148342
Horns DJ, Bellows AR, Hutchinson BT, et al. Argon laser trabeculoplasty for open angle glaucoma. A retrospective study of 380 eyes. Trans Ophthalmol Soc UK 1983;103:288-96.
Wang P, Akkach S, Andrew NH, et al. Selective Laser Trabeculoplasty: Outcomes of Multiple Repeat Treatments. Ophthalmol Glaucoma 2021;4:482-9.
DOI: https://doi.org/10.1016/j.ogla.2020.12.013
Tzimis V, Tze L, Ganesh J, Muhsen S, et al. Laser trabeculoplasty: an investigation into factors that might influence outcomes. Can J Ophthalmol 2011;46:305-9.
DOI: https://doi.org/10.1016/j.jcjo.2011.06.005
Hirabayashi MT, Rosenlof TL, An JA. Comparison of successful outcome predictors for MicroPulse® laser trabeculoplasty and selective laser trabeculoplasty at 6 months. Clin Ophthalmol 2019;13:1001-9.
DOI: https://doi.org/10.2147/OPTH.S205977
How to Cite
Nadeem, S. (2024). Frequency-doubled neodymium yttrium aluminum garnet (Nd:YAG) laser trabeculoplasty as adjuvant therapy for open-angle glaucomas. Laser Therapy, 31(1). https://doi.org/10.4081/ltj.2024.390
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.